The relative quantification trap
Most proteomics experiments today report relative changes — protein X is 1.8-fold higher in disease vs control. This is valuable for discovery, but it creates a fundamental problem when you need to answer the question: how much of protein X is actually present?
The clinical translation barrier
When a promising biomarker moves from discovery into validation, and eventually into clinical use, absolute concentration becomes essential. Clinicians work with reference ranges. Diagnostic tests have cut-off values. Neither can be derived from fold-change data alone.
The qRePS™ solution
ProteomEdge panels use heavy-isotope labeled recombinant protein standards titrated to physiological plasma concentrations. When co-digested with patient samples, they provide a single-point calibration that converts MS signal ratios into absolute molar concentrations — in every well, in every run, in every laboratory.
- No external calibration curves required
- Concentration values comparable across sites and instruments
- Median CV below 5.3% across all panels
This is what makes the difference between a discovery dataset and a clinical-grade measurement platform.